Purpose of review Peripheral T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin's lymphomas that are noted for their particularly poor prognosis. Their rarity has resulted in few data being available to allow formulation of optimal treatment approaches. There remains no widely accepted standard therapy. A new and increasing interest in studying these lymphomas is leading to advances in our understanding, which is widening options for management. Recent findings Historically, peripheral T-cell lymphomas were treated with strategies borrowed from management of aggressive B-cell lymphomas. Investigators have recognized the inadequacy of these approaches, and we are beginning to receive results, often preliminary, of studies specifically designed to evaluate T-cell lymphomas. These range from transplantation approaches, to better prognostic schemes and to attempts at molecular characterization, and new drugs are being developed specifically for their activity against T-cell lymphomas. Summary Research in T-cell lymphomas is still mainly preliminary and studies tend to be small. Nonetheless, our understanding of these disorders increasing, and data on new and hopefully better approaches are emerging.
机构:
Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USAJapanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
Ohmoto, Akihiro
Fuji, Shigeo
论文数: 0引用数: 0
h-index: 0
机构:
Osaka Int Canc Inst, Dept Hematol, 3-1-69 Otemae,Chuo Ku, Osaka 5418567, JapanJapanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan